Site content: Global

Order a test

CELLSEARCH® CTC Test

A simple, actionable blood test that helps you assess the prognosis of your patients with metastatic breast, prostate*, or colorectal cancer

Circulating tumor cell (CTC) analysis holds incredible promise as these cells, shed from tumors into the bloodstream, are detectable in peripheral blood and reflect real-time tumor evolution and heterogeneity.

The CELLSEARCH® CTC test has widely demonstrated clinical validity as a prognostic marker (1,2,3) and it has been cleared by the FDA for the enumeration of CTCs in patients with metastatic breast, prostate* and colorectal cancer (for more information on the full intended use and limitations please see the Instructions for Use at http://documents.cellsearchctc.com/).

The CELLSEARCH® CTC Test can be used throughout the course of treatment, together with radiological and clinical parameters, to monitor your patient’s status by showing you whether their prognosis is favorable or unfavorable at any given time. As few as 3 to 5 CTCs present in 7.5 mL of blood can predict a dramatic change in a patient’s prognosis and provide you with information required to make more informed treatment decisions.

Review clinical trial data and real case studies showing the role of CTC testing in patient management.

The CELLSEARCH® Circulating Tumor Cell (CTC) test is FDA-cleared for detecting CTCs in cancer patients with metastatic breast, prostate*, or colorectal cancer. (for more information on the full intended use and limitations please see the Instructions for Use at http://documents.cellsearchctc.com/)

*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer

References

  1. Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26(19):3213-3221.
  2. Cristofanilli M, Hayes DF, Budd GT, et al. J Clin Oncol. 2005;23(7):1420-1430.
  3. de Bono JS, Scher HI, Montgomery RB, et al. Clin Cancer Res. 2008;14(19):6302-6309.